IDEAYA Biosciences (IDYA) Receives a Hold From Leerink Partners

TipRanksDec 18 00:37 ET · Ratings

RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61

Moomoo NewsDec 17 12:31 ET · Ratings

Express News | Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight

BenzingaDec 17 09:03 ET

IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush

Dow JonesDec 17 08:44 ET · Ratings

IDEAYA Biosciences Analyst Ratings

BenzingaDec 17 08:30 ET · Ratings

The Independent Data Monitoring Committee Has Recommended Move-Forward Dose And The Completion Of Part 2A Dose Optimization For Ideaya Biosciences' Phase 2/3 Trial Of Darovasertib And Crizotinib Combination In First-line HLA-A2-Negative Metastatic...

BenzingaDec 17 06:05 ET